Intellectual Property Rights and Innovation: MNCs in Pharmaceutical Industry in India after TRIPS

Sudip Chaudhuri ()

Working Papers from eSocialSciences

Abstract: The paper discusses several patent cases to argue that MNCs are aggressively asserting their patent rights not for getting genuine patents which they are entitled to but for preventing generic competition. The paper also finds that the MNCs are more keen to import patented drugs and market these in the country rather than to manufacture these and contribute to technological progress.

Keywords: TRIPS; MNCs; Pharmaceutical; India; Patent; Drugs; manufacture; generic drugs; market; patent rights; technological progress; innovation; Novartis; Erlotinib. (search for similar items in EconPapers)
Date: 2015-03
Note: Institutional Papers
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.esocialsciences.org/Download/repecDownl ... &AId=6662&fref=repec

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ess:wpaper:id:6662

Access Statistics for this paper

More papers in Working Papers from eSocialSciences
Bibliographic data for series maintained by Padma Prakash ().